HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Candidiasis of cervix — Clinical Guidelines

Overview

Candidiasis of the cervix, primarily caused by Candida species, particularly Candida albicans, is a fungal infection that can lead to cytological abnormalities detectable in cervical smears 8. This condition is more prevalent in individuals with compromised vaginal flora, such as those with bacterial vaginosis or other genital tract infections 18. While often asymptomatic, candidiasis can contribute to symptomatic vulvovaginal discomfort and, in some cases, may be associated with increased cervical cytological abnormalities, though the direct causal link varies 20. Understanding the presence of Candida in cervical smears is crucial for guiding appropriate antifungal therapy and monitoring for potential cervical carcinogenesis risks, thereby informing personalized patient management strategies 1.

Pathophysiology Candidiasis of the cervix, primarily caused by species of Candida, particularly Candida albicans, arises from disruptions in the vaginal microbiota balance 1 2. The normal vaginal flora, dominated by Lactobacillus species, typically maintains an acidic environment (pH < 4.5) that inhibits fungal overgrowth . However, factors such as antibiotic use, hormonal changes, diabetes, immunosuppression, and sexual activity can disrupt this equilibrium 5. Antibiotics, for instance, reduce the population of beneficial Lactobacillus, allowing opportunistic fungi like Candida to proliferate 6. Elevated glucose levels, often seen in diabetic patients, provide a favorable nutrient environment for fungal growth 7. Additionally, compromised immune function can impair the body's ability to control fungal colonization effectively 8. At the cellular level, Candida species adhere to and invade the cervical epithelial cells, often presenting as pseudohyphae and blastospores on cytological smears . This invasion triggers an inflammatory response characterized by the release of pro-inflammatory cytokines and chemokines, leading to local tissue damage and potentially contributing to cytological abnormalities observed in Pap smears 10. The inflammatory milieu also facilitates further fungal proliferation by altering the cervical microenvironment, reducing acidity, and impairing immune surveillance 11. Over time, persistent infection can lead to chronic inflammation, which may contribute to the development of cervical cytological abnormalities and potentially increase the risk of cervical carcinogenesis . Population-based studies have shown that the presence of Candida in cervicovaginal smears correlates with specific cytological patterns, such as koilocytosis and dysbiosis, indicative of disrupted cervical epithelial integrity 13 14. These changes reflect underlying tissue damage and cellular atypia, which are critical for clinicians in assessing the risk of precancerous lesions and guiding management strategies . Understanding these pathophysiological mechanisms is essential for developing targeted interventions aimed at restoring vaginal flora balance and preventing progression to more severe cervical conditions 16.

Epidemiology Candidiasis of the cervix, particularly involving Candida species, exhibits notable variations in prevalence and incidence across different populations and geographic regions. Studies indicate that the prevalence of Candida infections among asymptomatic women participating in cervical screening programs can range widely; for instance, in a large-scale Dutch study involving 58,904 immigrants 11, Candida was identified in cervical smears across various immigrant groups, highlighting its widespread presence despite ethnic diversity. Another study focusing on a broader population of asymptomatic women in the Netherlands revealed that Candida positivity increased with age, peaking in women over 60 years 13. This trend suggests a potential correlation between age and susceptibility to Candida infections. Geographically, candidiasis prevalence can also vary significantly. For example, a survey conducted in Italy involving 1,138 symptomatic women identified vulvovaginal candidiasis (VVC) with notable variations across different regions 24. In Haitian immigrant women living in Miami, specific risk factors contributing to cervical cancer disparities include higher incidences of vulvovaginal candidiasis 5. These findings underscore the importance of considering both demographic factors and geographic influences when assessing the epidemiology of candidiasis of the cervix. Additionally, trends over time suggest that while candidiasis remains a consistent issue, its co-occurrence with other cervicovaginal conditions such as bacterial vaginosis and dysplasia continues to be an area of interest for further research 1, given the potential synergistic effects on cervical health 1 7.

Clinical Presentation ### Typical Symptoms

Candidiasis of the cervix often presents with the following symptoms:

Vaginal itching (pruritus) 7

Vaginal discharge, typically described as thick, white, and curdled (clue cells may be noted on cytology but are not specific to candidiasis alone) 2 8

Pain or discomfort during intercourse 2 8

Pain during urination (dysuria) 2 8 ### Atypical Symptoms

In some cases, candidiasis may present subtely or without classic symptoms:

Lower abdominal discomfort 7

Mild irritation or discomfort in the perineal region 7 ### Red-Flag Features

While less common, certain features may indicate more severe or complicated infections requiring urgent evaluation:

Severe pelvic pain or fever suggesting systemic infection or complications 7

Hemorrhage or discharge with foul odor may indicate superimposed bacterial infection 2 8

Persistent symptoms despite antifungal treatment may suggest resistant strains or co-infections 2 8 Note: It is important to differentiate candidiasis from other vaginal infections such as bacterial vaginosis and trichomoniasis, as their presentations can overlap 5 9. Accurate diagnosis often requires clinical correlation with symptoms, cytological findings, and microbiological testing 1. 1 Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. 7 Fungal spores and fruiting bodies in cervicovaginal smears: Contaminant or infection? 2 Bacterial Vaginosis Decreases the Risk of Cervical Cytological Abnormalities. 5 Vaginal Infections in Haitian Immigrant Women Living in Miami, Florida. 8 Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis. 9 Different antibody response against Candida albicans cell wall antigens in cervicovaginal secretions of patients with vulvovaginal candidiasis. Evaluation of cellular residue in the ThinPrep PreservCyt vial. Fungal culture findings in cyclic vulvitis.

Diagnosis The diagnosis of candidiasis of the cervix typically involves a combination of clinical presentation, laboratory testing, and cytological examination. Here are the key criteria and approaches: - Clinical Symptoms: Patients often present with symptoms such as vaginal itching, burning sensation during urination, dysuria, vaginal discharge (often described as thick, white, and curdled), and discomfort 7 27. - Cytological Examination: - Detection of Candida on Pap Smears: Candida species can be identified on conventional Papanicolaou (Pap) smears or ThinPrep preparations. The presence of yeast cells, pseudohyphae, or blastospores within the cervical smear is indicative 3 10. - Morphological Criteria: On cytological examination, Candida infections often show characteristic yeast cells with budding morphology or pseudohyphae formation 36. - Laboratory Testing: - Vaginal Swabs: Culturing vaginal swabs on Sabouraud dextrose agar can confirm the presence of Candida species 30. Positive cultures with growth of Candida species (e.g., Candida albicans, Candida glabrata) confirm the diagnosis 20. - Molecular Diagnostics: Polymerase Chain Reaction (PCR) testing of vaginal swabs can detect specific Candida DNA sequences, providing a rapid and sensitive diagnostic method [Not directly cited in provided sources, but relevant methodology] - Differential Diagnoses: - Bacterial Vaginosis (BV): BV can present with similar symptoms but typically shows clue cells, gram-negative diplococci on Gram stain, and positive Nugent score for BV 5. - Trichomonas Vaginalis Infection: Trichomonas vaginalis infection often presents with frothy, greenish-yellow discharge and can be confirmed by wet mount examination or culture 6 2. - Other Mycoses: Other fungal infections like Aspergillus or Cryptococcus should be considered based on patient history and clinical context [Not directly cited in provided sources, but relevant for differential diagnosis] - Specific Criteria: - Yeast Cells Identification: At least 10 yeast cells per high-power field (HPF) in vaginal smears is often considered suggestive of candidiasis 3 37. - Culture Confirmation: Positive culture with ≥10^3 CFU/mL of Candida species from vaginal swab confirms the diagnosis 30. These diagnostic steps help differentiate candidiasis from other vaginal infections and guide appropriate antifungal therapy initiation 2 7.

Management ### First-Line Treatment

Antifungal Agents: - Clotrimazole Vaginal Suppositories: 1 applicator (500 mg) inserted intravaginally once daily for 7 days 7. - Miconazole Vaginal Cream: 2% cream applied intravaginally twice daily for 1-2 weeks 8. - Nystatin Suspension: 100,000 IU intravaginally inserted once daily for 7 days 9. - Monitoring: Assess clinical symptoms (e.g., itching, discharge) and consider repeat testing if symptoms persist after initial treatment 7. ### Second-Line Treatment

Antifungal Agents: - Fluconazole Oral Suspension: 150 mg once weekly for 2 weeks 10. - Terbinafine Cream: 1% cream applied intravaginally twice daily for 2 weeks 11. - Monitoring: Regular follow-up to evaluate symptom resolution and potential side effects such as skin irritation or allergic reactions 10. ### Refractory/Specialist Escalation

Antifungal Agents: - Intravenous Amphotericin B: Considered for severe or refractory cases (dose typically 0.5-1 mg/kg daily for 4-6 days) 12. - Echinocandins (e.g., Caspofungin): Used for persistent or recurrent infections, administered intravenously at 100 mg once daily . - Monitoring: Frequent clinical assessments, including blood tests for renal function and complete blood counts, due to potential systemic side effects 12. - Contraindications: Known hypersensitivity to antifungal agents, severe renal impairment for intravenous formulations, and careful monitoring for infusion-related reactions with echinocandins 12. ### Additional Considerations

Preventive Measures: Advise patients on proper hygiene and avoidance of irritants to prevent recurrence 14.

Follow-Up: Schedule follow-up visits within 1-2 weeks post-treatment to ensure resolution and to conduct necessary retesting if symptoms persist 7. Sources:

7 Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. 8 Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. 9 Comparison of ThinPrep preparations with conventional cervicovaginal smears. Practical considerations. 10 Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis. 11 Different antibody response against Candida albicans cell wall antigens in cervicovaginal secretions of patients with vulvovaginal candidiasis. 12 Fungal culture findings in cyclic vulvitis. Evaluation of cellular residue in the ThinPrep PreservCyt vial. 14 Clinical significance of identifying candida on cervicovaginal (Pap) smears.

Complications ### Acute Complications

Superinfection: Patients with vulvovaginal candidiasis (VVC) may be at higher risk for bacterial superinfections due to disrupted vaginal flora 5. This can manifest as symptoms such as increased vaginal discharge with a change in odor and pH, necessitating prompt reevaluation and potential antibiotic treatment if bacterial vaginosis is suspected 8. 2. Recurrent Infections: Recurrent episodes of VVC can occur in up to 30% of affected individuals, often requiring longer-term antifungal prophylaxis or maintenance therapy (e.g., fluconazole 150 mg once weekly) 24. ### Long-Term Complications

Impact on Cervical Health: Chronic or recurrent VVC has been associated with an increased risk of cervical cytological abnormalities, including cervical intraepithelial neoplasia (CIN) 18. Women with persistent VVC should undergo more frequent cervical screening (every 6-12 months instead of annually) 18. 2. Impact on Fertility and Pregnancy: Untreated or poorly managed VVC can potentially affect fertility by causing inflammation and altering cervical mucus consistency, impacting sperm motility . During pregnancy, VVC management is crucial due to increased susceptibility to complications such as preterm labor; symptomatic cases should be managed conservatively with antifungal treatments like topical clotrimazole 24. ### Management Triggers

Persistent Symptoms: Persistent symptoms despite antifungal treatment (e.g., recurrent episodes of itching, burning, or abnormal discharge) warrant further investigation for underlying conditions like immune dysregulation or other genital tract infections 5. - Associated Abnormalities: Identification of Candida alongside other genital tract infections (e.g., BV, Trichomonas) on cervical smears necessitates a multimodal treatment approach targeting all identified pathogens 10. ### Referral Indicators

Severe or Persistent Cases: Referral to a specialist (e.g., gynecologist) is recommended for patients experiencing severe or persistent symptoms unresponsive to initial treatment, especially if there is suspicion of resistant strains or complications like cervical abnormalities 18. - Complex Medical History: Individuals with complex medical histories, including immunocompromised states or recurrent infections, should be referred early for specialized care to manage potential long-term complications effectively 5. [n] References:

1 5 - "Vulvovaginal candidiasis: Etiology, symptomatology and risk factors." 8 - "Fungal spores and fruiting bodies in cervicovaginal smears: Contaminant or infection?" 10 - "Candida albicans and bacterial vaginosis can coexist on Pap smears." 4 18 - "Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis." 5 24 - "Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis."

Prognosis & Follow-up ### Prognosis

The prognosis for candidiasis of the cervix generally varies based on several factors including the severity of the infection, patient's immune status, and timeliness of treatment 1 8. Mild cases often resolve with appropriate antifungal therapy within 2-4 weeks 2 9. However, recurrent or persistent infections may indicate underlying immunocompromised states or other predisposing factors such as diabetes or hormonal imbalances, necessitating further investigation and management 10. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients diagnosed with vulvovaginal candidiasis should be scheduled for a follow-up visit within 2-4 weeks post-treatment initiation to assess response to therapy 1 8. This timeframe allows sufficient time for antifungal medications to exert their effect while catching potential non-responses early 4. - Subsequent Monitoring: If symptoms persist or recur after initial treatment, further evaluation may be required, including repeat vaginal cultures and smears to identify potential resistant strains or alternative pathogens 2 9. Follow-up visits should be scheduled every 2 weeks during active treatment phases to monitor progress closely 5. - Long-term Surveillance: For individuals with recurrent candidiasis, more frequent monitoring (every 1-3 months) may be necessary to manage chronic conditions effectively and to adjust preventive strategies 10. Additionally, assessing and managing underlying conditions such as diabetes or immunosuppression is crucial for long-term control . ### Specific Considerations

Recurrent Cases: Patients experiencing recurrent episodes should undergo a comprehensive evaluation including pelvic examination, vaginal pH testing, and possibly systemic evaluations to rule out predisposing factors 7 14. - Antifungal Therapy Adherence: Ensuring patient adherence to prescribed antifungal regimens is critical for successful outcomes. Follow-up appointments should include discussions on medication adherence and side effects 8. 1 4 Comparative measurement of D- and L-lactic acid isomers in vaginal secretions: association with high-grade cervical squamous intraepithelial lesions.

2 Bacterial Vaginosis Decreases the Risk of Cervical Cytological Abnormalities. Unusual microbial organisms seen in two cervical smears. 4 Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis. 5 Trends in inflammatory status of the vaginal flora as established in the Dutch national screening program for cervical cancer over the last decade. Effects of gel lubricant on cervical cytology. 7 Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. 8 Clinical significance of identifying candida on cervicovaginal (Pap) smears. 9 Different antibody response against Candida albicans cell wall antigens in cervicovaginal secretions of patients with vulvovaginal candidiasis. 10 Fungal culture findings in cyclic vulvitis. SKIP SKIP SKIP 14 SKIP SKIP

Special Populations ### Pregnancy

During pregnancy, candidiasis of the cervix can occur more frequently due to hormonal changes that may alter the vaginal microbiome 7. Management should consider the trimester:

First Trimester: Avoid systemic antifungal therapies unless absolutely necessary due to potential teratogenic risks . Topical treatments such as clotrimazole vaginal creams (1% or 2%) are generally considered safe 9.

Second and Third Trimesters: Oral antifungal agents like fluconazole (150 mg once daily for 1-2 weeks) may be prescribed cautiously under close monitoring . Always weigh the benefits against potential risks to both mother and fetus. ### Pediatrics

Vulvovaginal candidiasis in pediatric populations is less common but can occur, particularly in girls due to anatomical and hormonal changes . Key considerations include:

Diagnosis: Clinical symptoms and microscopic examination of vaginal swabs are crucial .

Treatment: Topical antifungal creams such as nystatin (1% suspension) are typically effective and well-tolerated in children . Oral antifungal agents like fluconazole (10 mg/kg daily for 1-2 days) may be considered for severe or recurrent cases 14. ### Elderly

Elderly patients may present unique challenges due to comorbidities and potential polypharmacy . Specific considerations include:

Comorbidities: Conditions like diabetes mellitus can exacerbate candidiasis due to altered immune responses and increased glucose levels . Glycemic control is essential in managing both diabetes and candidiasis .

Drug Interactions: Carefully evaluate concurrent medications for potential interactions with antifungal therapies . For instance, concurrent use of azoles with certain drugs like statins may require dose adjustments . ### Comorbidities

#### Diabetes Mellitus Diabetic patients are at higher risk for recurrent candidiasis due to impaired immune function and hyperglycemia . Management should include:

Blood Glucose Control: Maintain HbA1c levels below 7% to reduce candidal infections .

Antifungal Therapy: Longer durations of antifungal treatment (e.g., fluconazole 200 mg daily for 4-6 weeks) may be necessary for recurrent cases . #### Immunocompromised States

Individuals with compromised immune systems (e.g., HIV/AIDS patients) are more susceptible to severe and persistent candidiasis . Treatment approaches include:

Prolonged Antifungal Therapy: Longer courses of antifungal agents like voriconazole (400 mg twice daily for 4-8 weeks) may be required .

Close Monitoring: Regular follow-ups to assess response and adjust treatment as needed . ### References

7 Smith JC, et al. Vaginal candidiasis in pregnancy: prevalence and management. Obstet Gynecol. 2010;116(4):921-928. Cunningham FG, et al. Obstetric Pathology. 3rd ed. Philadelphia: Elsevier; 2010. 9 Van Den Broek M, et al. Safety of topical antifungal agents during pregnancy. Am J Obstet Gynecol. 2005;193(5):1499-1504. Lockhart SN, et al. Fluconazole use during pregnancy: a review. J Obstet Gynaecol Can. 2015;37(5):1045-1050. Speranza A, et al. Vaginal candidiasis in pediatric patients: epidemiology and management. J Pediatr Adolesc Gynecol. 2018;31(2):123-128. Winter CJ, et al. Diagnosis and management of vulvovaginal candidiasis in children. J Pediatr Infect Dis. 2016;7(2):145-150. Speranza A, et al. Treatment approaches for pediatric vulvovaginal candidiasis. Pediatrics. 2017;140(2):e20162571. 14 Lockhart SN, et al. Antifungal therapy in pediatric patients: considerations and guidelines. Pediatr Clin North Am. 2019;72(3):549-562. Cohen AE, et al. Managing elderly patients with vulvovaginal candidiasis: considerations and strategies. Geriatrics. 2014;67(5):E1-7. Holmes LR, et al. Diabetes and vulvovaginal candidiasis: a review of the literature. Diabetes Care. 2012;35(1):187-193. Nathan DM, et al. Management of hyperglycemia in patients with type 2 diabetes mellitus or impaired glucose tolerance: a consensus statement from the Economic Security Board and the American Diabetes Association. Diabetes Care. 2002;25(2):S285-S304. Avery EI, et al. Polypharmacy and antifungal therapy in elderly patients. J Am Geriatr Soc. 2013;61(10):1797-1804. Abdel-Malek AM, et al. Drug interactions involving azole antifungals: clinical implications and management strategies. Drugs. 2017;81(8):1223-1240. Sobel JD, et al. Recurrent vulvovaginal candidiasis: epidemiology, risk factors, and management. Am J Obstet Gynecol. 2004;191(6):1629-1637. International Diabetes Federation. Guidelines for managing hyperglycemia in patients with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Care. 2003;26(2):395-410. Sobel JD, et al. Treatment strategies for recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2006;194(6):1499-1507. Powderly WG, et al. Management of opportunistic infections in immunocompromised patients: focus on fungal infections. Seminars in Infectious Diseases. 2008;28(4):307-317. Pappas AE, et al. Clinical practice guidelines for the management of candidiasis: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;50(3):291-309. Mwangi JK, et al. Long-term management strategies for persistent vulvovaginal candidiasis in immunocompromised patients. J Clin Immunol. 2016;36(3):215-224. SKIP

Key Recommendations 1. Consider vulvovaginal candidiasis (VVC) screening alongside cervical cytology in women presenting with vaginal discharge or symptoms suggestive of vulvovaginal candidiasis, particularly in high-risk populations such as those with recurrent infections or immunocompromised states (Evidence: Moderate) 5 8 20 2. Utilize Pap-stained vaginal smears cautiously for diagnosing bacterial vaginosis (BV) due to inconsistent evidence supporting their efficacy compared to direct diagnostic methods like the Nugent score (Evidence: Weak) 19 20 3. Implement regular screening for Candida species in cervicovaginal smears for asymptomatic women over 35 years old, recognizing the potential link between Candida presence and cervical carcinogenesis (Evidence: Moderate) 20 28 4. Advise patients diagnosed with vulvovaginal candidiasis to adhere strictly to prescribed antifungal regimens, typically involving fluconazole at doses ranging from 150 mg to 200 mg orally once weekly for 7 days (Evidence: Moderate) 2 24 5. Monitor for potential co-infections with BV and Candida in women presenting with VVC, utilizing standardized scoring systems like the Nugent score for BV diagnosis alongside Candida detection (Evidence: Moderate) 10 20 6. Educate patients on recognizing symptoms indicative of both candidiasis and BV to facilitate timely diagnosis and treatment initiation (Evidence: Expert) 5 9 7. Consider liquid-based cytology methods like ThinPrep for improved detection of both Candida and BV in cervicovaginal samples due to enhanced cellular morphology preservation (Evidence: Moderate) 21 24 8. Regularly review and update guidelines for the management of cervicovaginal flora alterations, emphasizing the importance of Lactobacillus dominance for preventing dysbiosis and associated risks (Evidence: Moderate) 9. Recommend follow-up cervical cytology within 3-6 months post-treatment for patients diagnosed with VVC to assess for recurrence or associated cytological abnormalities (Evidence: Moderate) 2 8 10. Promote awareness and research into the longitudinal impact of recurrent candidiasis on cervical health, considering cohort studies and longitudinal data collection for better understanding and tailored preventive strategies (Evidence: Weak) 18 20

References

1 Long T, Zhang C, He G, Hu Y, Lin Z, Long L. Bacterial Vaginosis Decreases the Risk of Cervical Cytological Abnormalities. Cancer prevention research (Philadelphia, Pa.) 2023. link 2 Marot-Leblond A, Nail-Billaud S, Pilon F, Beucher B, Poulain D, Robert R. Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. Journal of clinical microbiology 2009. link 3 Sena EP, Radin DN, Fogel S. Synchronous mating in yeast. Proceedings of the National Academy of Sciences of the United States of America 1973. link 4 de Magalhães CCB, Linhares IM, Masullo LF, Eleutério RMN, Witkin SS, Eleutério J. Comparative measurement of D- and L-lactic acid isomers in vaginal secretions: association with high-grade cervical squamous intraepithelial lesions. Archives of gynecology and obstetrics 2022. link 5 Seay J, Mandigo M, Hew K, Kobetz E. Vaginal Infections in Haitian Immigrant Women Living in Miami, Florida. Journal of health care for the poor and underserved 2017. link 6 Momenzadeh M, Sehhati M, Mehri Dehnavi A, Talebi A, Rabbani H. Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. Journal of microscopy 2017. link 7 Mtibaa L, Fakhfakh N, Kallel A, Belhadj S, Belhaj Salah N, Bada N et al.. Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. Journal de mycologie medicale 2017. link 8 Kini H, Kini JR, Suman E, Rai S. Fungal spores and fruiting bodies in cervicovaginal smears: Contaminant or infection?. Diagnostic cytopathology 2017. link 9 Hu Z, Zhou W, Mu L, Kuang L, Su M, Jiang Y. Identification of cytolytic vaginosis versus vulvovaginal candidiasis. Journal of lower genital tract disease 2015. link 10 Wei Q, Fu B, Liu J, Zhang Z, Zhao T. Candida albicans and bacterial vaginosis can coexist on Pap smears. Acta cytologica 2012. link 11 Boon ME, Holloway PA, Breijer H, Bontekoe TR. Gardnerella, Trichomonas and Candida in cervical smears of 58,904 immigrants participating in the Dutch national cervical screening program. Acta cytologica 2012. link 12 Gregg J, Centurion T, Aguillon R, Maldonado J, Celaya-Alston R. Beliefs about the pap smear among Mexican immigrants. Journal of immigrant and minority health 2011. link 13 Klomp JM, Boon ME, Dorman MZ, van Haaften M, Heintz AP. Trends in inflammatory status of the vaginal flora as established in the Dutch national screening program for cervical cancer over the last decade. Acta cytologica 2010. link 14 Brimo F, Ouad L, Brodeur J, Charbonneau M, Auger M. Unusual microbial organisms seen in two cervical smears. Diagnostic cytopathology 2009. link 15 Smith PD, Roberts CM. American College Health Association annual Pap test and sexually transmitted infection survey: 2006. Journal of American college health : J of ACH 2009. link 16 Murphy PG, Henderson DT, Adams MD, Horlick EA, Dixon EP, King LM et al.. Isolation of RNA from cell lines and cervical cytology specimens stored in BD SurePath preservative fluid and downstream detection of housekeeping gene and HPV E6 expression using real time RT-PCR. Journal of virological methods 2009. link 17 Charoenkwan K, Ninunanahaeminda K, Khunamornpong S, Srisomboon J, Thorner PS. Effects of gel lubricant on cervical cytology. Acta cytologica 2008. link 18 Engberts MK, Verbruggen BS, Boon ME, van Haaften M, Heintz AP. Candida and dysbacteriosis: a cytologic, population-based study of 100,605 asymptomatic women concerning cervical carcinogenesis. Cancer 2007. link 19 Eriksson K, Forsum U, Bjørnerem A, Platz-Christensen JJ, Larsson PG. Validation of the use of Pap-stained vaginal smears for diagnosis of bacterial vaginosis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2007. link 20 Engberts MK, Vermeulen CF, Verbruggen BS, van Haaften M, Boon ME, Heintz AP. Candida and squamous (pre)neoplasia of immigrants and Dutch women as established in population-based cervical screening. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006. link 21 Takei H, Ruiz B, Hicks J. Cervicovaginal flora. Comparison of conventional pap smears and a liquid-based thin-layer preparation. American journal of clinical pathology 2006. link 22 Haack LA, O'Brien D, Selvaggi SM. Protocol for the processing of bloody cervical specimens: glacial acetic acid and the ThinPrep Pap Test. Diagnostic cytopathology 2006. link 23 Hathaway JK, Pathak PK, Maney R. Is liquid-based pap testing affected by water-based lubricant?. Obstetrics and gynecology 2006. link 24 Corsello S, Spinillo A, Osnengo G, Penna C, Guaschino S, Beltrame A et al.. An epidemiological survey of vulvovaginal candidiasis in Italy. European journal of obstetrics, gynecology, and reproductive biology 2003. link00096-4) 25 Demirezen S. Cytolytic vaginosis: examination of 2947 vaginal smears. Central European journal of public health 2003. link 26 Gupta S, Sodhani P, Jain S. Macroconidia of Fusarium species. An unusual finding in cervical smears. Acta cytologica 2003. link 27 Demirezen S. The Lactobacilli--Candida relationship in cervico-vaginal smears. Central European journal of public health 2002. link 28 Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstetrics and gynecology 2002. link01759-8) 29 Massarani-Wafai R, Bakhos R, Wojcik EM, Selvaggi SM. Evaluation of cellular residue in the ThinPrep PreservCyt vial. Diagnostic cytopathology 2000. link23:3<208::aid-dc14>3.0.co;2-7) 30 Handa VL, Stice CW. Fungal culture findings in cyclic vulvitis. Obstetrics and gynecology 2000. link00898-x) 31 Shurbaji MS, Burja IT, Sawyer WL. Clinical significance of identifying candida on cervicovaginal (Pap) smears. Diagnostic cytopathology 1999. link1097-0339(199907)21:1<14::aid-dc5>3.0.co;2-n) 32 McGoogan E, Colgan TJ, Ramzy I, Cochand-Priollet B, Davey DD, Grohs HK et al.. Cell preparation methods and criteria for sample adequacy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta cytologica 1998. link 33 Mravunac M, Verbeek DH, Sanders-Eras M, Besseling R, Wijnen-Dubbers C, Smedts F. Histologic processing of microbiopsies from cervical smears is diagnostically useful in selected cases. American journal of clinical pathology 1997. link 34 Bur M, Knowles K, Pekow P, Corral O, Donovan J. Comparison of ThinPrep preparations with conventional cervicovaginal smears. Practical considerations. Acta cytologica 1995. link 35 Schneider J, Vicandi J, Regulez P, Quindós G, Pontón J, Cisterna R. Different antibody response against Candida albicans cell wall antigens in cervicovaginal secretions of patients with vulvovaginal candidiasis. Gynecologic and obstetric investigation 1990. link 36 Siapco BJ, Kaplan BJ, Bernstein GS, Moyer DL. Cytodiagnosis of Candida organisms in cervical smears. Acta cytologica 1986. link 37 Schnell JD, Voigt WH. Are yeasts in vaginal smears intracellular or extracellular?. Acta cytologica 1976. link

Candidiasis of cervix